Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin

A method of increasing probability of maintaining an achieved complete response for at least 15 months post-treatment initiation comprising the step of:

• administering to a patient in need thereof nonsurgical primary chemoablation with a thermally gelling pharmaceutical composition comprising 75 mg of mitomycin once weekly for six weeks,
• wherein the patient in need thereof has recurrent low-grade intermediate-risk non- muscle-invasive bladder cancer (NMIBC),
• wherein the patient in need thereof had a previous episode of low-grade NMIBC that was treated with transurethral resection of bladder cancer (TURBT), and
• wherein the thermally gelling pharmaceutical composition was prepared by mixing a composition comprising mitomycin together with a thermoreversible hydrogel comprising about 27% (w/w) Poloxamer 407 and about 0.18% (w/w) hydroxypropylmethylcellulose based on a total weight of the thermoreversible hydrogel.